Search the Newsreel

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

CalciMedica announced FDA alignment on the Phase 2b trial design for Auxora in acute pancreatitis (AP), identifying new-onset severe respiratory failure as the primary endpoint. The FDA also agreed on evaluating elevated lactate dehydrogenase (LDH) as a potential biomarker to identify high-risk patients. This …

Cimpress NV earnings missed by $0.24, revenue fell short of estimates

Cimpress (NASDAQ:CMPR) Issues Earnings Results

Chimera Investment (CIM) Projected to Announce Earnings on Wednesday

CMPR5892539 Bond Profile — Key Metrics

This article provides key metrics for the Cimpress plc 7.375% 15-SEP-2032 bond, identified as CMPR5892539. It details facts such as the issuer, issue and maturity dates, outstanding amount, face value, coupon rate, and minimum denomination. The article also describes Cimpress Plc's business operations across …

Cimpress Number of Employees 2026 | Employee Count & Headcount Data

This article details Cimpress Plc's employee count and workforce trends as of March 2026. Cimpress has approximately 15,608 employees worldwide, marking a 2.1% growth since 2023 but a 0.9% year-over-year decline in 2026. The company is actively hiring, with 335 job postings in 2026, …

CalciMedica Inc (CALC) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health overview of CalciMedica Inc (CALC), focusing on its profitability and balance sheet analysis. As of the close on July 27, 2026, the company's stock was trading at $0.708, experiencing a 6.78% drop. The content highlights key financial data …

Colonial Sfl Socimi SA (WBO:COL) Q2 2026 Earnings Call Highlights: Strong Rental Income Growth ...

This article first appeared on GuruFocus. Gross Rental Income: 207 million, up 5% year-on-year. Recurring Earnings: 111 million, 4% growth year-on-year. EPRA EPS: 0.178, up 4% year-on-year. Occupancy Rate: Increased by 200 basis points to 94%. Net Tangible Assets: 6.0 billion, with a per …

Are Consumer Discretionary Stocks Lagging Cimpress (CMPR) This Year?

The Consumer Discretionary group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Cimpress (CMPR) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to …

CalciMedica Inc (CALC) Institutional Confidence

This article provides details on the institutional confidence in CalciMedica Inc (CALC), listing key shareholders and their respective shareholdings. The data includes the number of shares held by entities like Sanderling Ventures and Alafi Capital Company, as well as changes in their holdings. The …

CalciMedica Inc (CALC) Cash Flow

This article provides a detailed cash flow statement for CalciMedica Inc (CALC), including operating, investing, and financing cash flows presented quarterly. It highlights key financial figures such as net income from continuing operations, capital expenditures, and free cash flow for various fiscal quarters. The …

Cimpress PLC (CMPR) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Cimpress PLC (CMPR), including operating, investing, and financing cash flows, along with changes in working capital and other non-cash items. It also features a FAQ section explaining key cash flow metrics and …

Cimpress PLC (CMPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Cimpress PLC (CMPR), focusing on its consolidated revenue by region. As of the latest available data updated on April 6, the company generated $547.68 million from Europe, accounting for 52.55% of total revenue, and $452.48 million from …

Cimpress PLC (CMPR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Cimpress PLC's (CMPR) stock performance, including its current price, market capitalization, and P/E ratio. It specifically highlights the company's dividend history, noting that no dividends have been distributed in the past five years. The page serves as a …

Cimpress Plc Revenue Breakdown – LSX:A2PWHR

This article provides a revenue breakdown for Cimpress Plc (LSX:A2PWHR), highlighting its top-performing segment and geographical contributions for the last financial year. The company generated €2.89 billion, with Vista being the largest segment and the United States contributing the most geographically.

Chimera Investment (CIM) Advances 1.38%: Testing Resistance Levels - Pairs Trade

CalciMedica, Inc. Revenue Breakdown – NASDAQ:CALC

This article provides a basic overview of CalciMedica, Inc. (NASDAQ:CALC) financials, specifically referencing its revenue breakdown section on TradingView. It indicates that the company's financial data, including segments and regional performance, is available for review, though the specific breakdown content is not included in …

TradingKey

This article provides a detailed financial overview of CalciMedica Inc (CALC), focusing on its quarterly and annual income statements. It presents a comprehensive table of income statement metrics from FY2020Q3 to FY2026Q1, including operating expenses, R&D expenses, operating profit, net income, and EPS. The …

Cimpress (CMPR) Stock Still Looks Above Fair Value As Earnings Face Pressure

Cimpress (CMPR) stock has doubled over the past year, but its current valuation, with a P/E ratio of 52.1x, appears significantly overvalued compared to the industry average and a fair estimated P/E of 24.7x. The article suggests that despite strong recent performance, the stock's …

CALC|CalciMedica Inc|Price:0.721|Chg%:-0.039

CalciMedica Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunologic diseases by inhibiting CRAC channels. Their lead product candidate, Auxora, is in Phase IIb trials for acute pancreatitis and supporting Phase I/II studies for asparaginase-induced pancreatic toxicity. The …

Cimpress PLC (CMPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cimpress PLC (CMPR), outlining both its major individual and institutional shareholders. Key information includes the proportions held by top investors like Prescott General Partners LLC and Janus Henderson Investors, a breakdown of shareholder types, and historical institutional …

CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of CalciMedica Inc.'s (CALC) shareholder structure, detailing major shareholders and institutional holdings. It lists the top individual and venture capital firms holding significant proportions of shares, along with statistics on institutional ownership over several quarters. The data includes the …

CMPR|Cimpress PLC|Price:97.780|Chg%:+0.430

This article provides an analysis of Cimpress PLC (CMPR) stock, highlighting its strong fundamentals, high growth potential, and fair valuation within the Professional & Commercial Services industry. It notes a high institutional ownership and recent "Strong Buy" ratings from analysts. The stock's performance indicates …

CalciMedica (NASDAQ: CALC) files to register 56M shares from June 2026 PIPE

CalciMedica (NASDAQ: CALC) has filed a resale registration statement (S-3) for up to 56,020,287 shares of common stock. These shares are intended for resale by selling stockholders and include shares issued in a June 23, 2026 private placement, as well as shares issuable upon …

CalciMedica (NASDAQ: CALC) plans reverse split, 7.5M-share equity plan boost and warrant votes

CalciMedica (NASDAQ: CALC) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-10, an increase of 7.5 million shares to its 2023 Equity Incentive Plan, and the approval of warrant issuances related to a recent private placement. These …

Chimera Investment Corporation Announces Second Quarter 2026 Earnings Release and Conference Call Date

NEW YORK, July 24, 2026--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) announced today that it will release financial results for the second quarter ended June 30, 2026, before the market opens on Wednesday, August 5, 2026. The company will host a conference call and live …

Chimera schedules 8:30 a.m. webcast for June-quarter results

CMPR5892541 Bond Redemption Profile

This article provides a bond redemption profile for Cimpress plc's 7.375% bond due September 15, 2032, identified as CMPR5892541. It explains what bond redemption entails—the complete repayment of principal and accrued interest—and details key redemption information including type, date, and amount, along with the …

CMPR5892540 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Cimpress plc's CMPR5892540 bond, detailing its coupon rate and payment schedule. The bond has a current coupon rate of 7.38%, with the next payment planned for September 15, 2026. The profile also highlights additional coupon data …

CMPR5892540 Bond Risk Profile

This article provides a risk profile for the Cimpress plc 7.375% 15-SEP-2032 bond, identified as CMPR5892540. It highlights key metrics for assessing credit risk, including security level, inflation protection, and issuer rating, to help investors make informed decisions. The piece also mentions access to …

Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC

The article displays the "Price to earnings forward" metric for CalciMedica, Inc. (NASDAQ: CALC) on the TradingView platform. It shows that the value is currently not available, indicating a focus on financial data for this specific company.

Cimpress (CMPR) to Release Quarterly Earnings on Wednesday

US17186HAH57 Bond Redemption Profile

This article provides a bond redemption profile for Cimpress plc 7.375% 15-SEP-2032 (US17186HAH57). It explains what bond redemption is and details where to find information regarding redemption type, date, amount, and the sinking fund schedule, highlighting its importance for investors. The content encourages users …

US17186HAH57 Bond Profile — Key Metrics

This article provides key metrics for the Cimpress plc 7.375% 15-SEP-2032 bond (US17186HAH57), traded on the Vienna Stock Exchange. It details the bond's issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The bond is issued by Cimpress Plc, …

CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a beneficial ownership of 1,556,081 shares of CalciMedica (CALC) common stock, representing a 5.1% equity stake. This information was reported in a Schedule 13G SEC filing. Heights Capital Management acts as the investment manager …

Zacks.com featured highlights include Dycom Industries, Cimpress, The Marcus and Flexsteel Industries

For Immediate Release Chicago, IL – July 20, 2026 – Stocks in this week's article are Dycom Industries, Inc. DY, Cimpress plc CMPR, The Marcus Corp. MCS and Flexsteel Industries, Inc. FLXS. Buy 4 Stocks with Rising Cash Flows to Enrich Your Portfolio We …